ASCO Gastrointestinal Cancers Symposium

In the CheckMate 649 trial, durable survival benefit was achieved with Nivolumab plus chemotherapy in patients with gastric or gastroesophageal junction cancer.

The combination of transarterial chemoembolization, lenvatinib, and PD-1 checkpoint blockade demonstrated tolerable safety and efficacy in patients with unresectable advanced hepatocellular carcinoma.

Sintilimab treatment in pancreatic cancer shows mixed efficacy results in the phase 3 CISPD3 trial.

In the phase 3 KEYNOTE-394 trial, pembrolizumab and best supportive care prolongs survival in patients.

During the 2022 Gastrointestinal Cancers Symposium, Zev A. Wainberg, MD, predicts how gastric cancer treatment will look in the near future.

In a phase 3 study, patients with biliary tract cancer who received adjuvant oral fluoropyrimidine derivative S-1 lived longer than patients who underwent surgery.

According to updated findings from a cohort of the KRYSTAL-1 trial adagrasib may be active in previously treated KRAS G12C¬–mutant gastrointestinal tumors.

Results from the phase 3 KEYNOTE-062 study appear mixed for both pembrolizumab monotherapy versus chemotherapy and pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Single nucleotide polymorphisms such as NOTCH1, SEMA4D, NLRC5, and IL6R, may be predictive of nivolumab toxicity in advanced gastric cancer.

Results presented during the 2022 Gastrointestinal Cancers Symposium showed that 58.6% of evaluable patients experienced complete regression and fibrosis with no tumor cells.

Updated survival results from the phase 2 DESTINY-Gastric01 trial reveal the survival benefit of trastuzumab deruxtecan HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma.

In patients with previously treated advanced hepatocellular carcinoma (HCC), single-agent pembrolizumab (Keytruda) maintained numerical improvement in survival (OS), updated findings randomized phase 3 KEYNOTE-240 trial show.

Results from the phase 3 IMbrave150 clinical trial showed that the combination of atezolizumab and bevacizumab continued to demonstrate improvement in survival compared with sorafenib in previously untreated patients with advanced hepatocellular carcinoma.

In a phase 2 clinical trial, the oral, FGFR1-3 selective tyrosine kinase inhibitor, infigratinib correlated with promising anticancer activity in addition to manageable safety as treatment of patients with chemotherapy-refractory cholangiocarcinoma whose tumors harbor FGFR2 fusions.

The final overall survival analysis of the phase 3 ClarIDHy trial demonstrated that treatment with ivosidenib tablets achieved a 21% reduction in the risk of death in patients with IDH1-mutant cholangiocarcinoma compared with placebo.

Ghasson K. Abou-Alfa, MD, discusses the rapid evolution observed in the treatment landscape of hepatocellular carcinoma over the last few years.

Step counts appeared to correlate with self-reported quality of life during the first 2 weeks of treatment with SM-88 in patients with metastatic pancreatic cancer, the results of a preliminary exploratory analysis from part 2 of the phase 2/3 TYME-88-Panc trial showed.

In patients with esophageal cancer, chemotherapy with or without added pembrolizumab led to similar health-related quality of life results over 18 weeks, according to findings from the phase 3 KEYNOTE-590 study.

In the frontline setting of FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma, the combination of bemarituzumab combined with mFOLFOX6 achieved a 56% reduction in the risk of disease progression or death compared with placebo.

Andrew X. Zhu, MD, PhD, discusses the evolving treatment landscape for patients with hepatocellular carcinoma.

Neoadjuvant chemotherapy regimens were not found to increase the risk for perioperative complications in patients who have potentially resectable advanced thoracic esophageal cancer, according to data from the phase 3 JCOG 1109 trial that were virtually presented at the 2021 Gastrointestinal Cancers Symposium.

In multiple gastrointestinal tumor types, the combination of the anti-angiogenic multikinase inhibitor lenvatinib plus the anti-PD-1 antibody pembrolizumab demonstrated promising antitumor activity and a manageable safety profile, according to data presented at the 2021 ASCO Gastrointestinal Cancers Symposium.

In a retrospective, real-world analysis of patients with unresectable hepatocellular carcinoma in the United States, investigators observed that lenvatinib alone was effective as first-line treatment.

Esophageal-specific and general quality of life was improved in patients with esophageal/gastroesophageal cancer who received nivolumab in the Checkmate 577 clinical trial, according to subgroup analysis data presented during the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

The addition of pembrolizumab and trastuzumab to the combination cisplatin plus capecitabine was able to effectively treat HER2-positive advanced gastric and gastroesophageal junction cancer, regardless of PD-L1 expression in the phase 1b/2 PANTHERA trial.

Camrelizumab in combination with apatinib demonstrated encouraging clinical efficacy as a second-line treatment of patients with esophageal squamous cell carcinoma and demonstrated acceptable safety in a single-arm, open-label phase 2 clinical trial.

Roughly 40% of patients with advanced, progressive gastroenteropancreatic neuroendocrine tumors treated with pembrolizumab in combination with lanreotide achieved stable disease, according to results from the phase 1b/2 PLANET clinical trial presented during the 2021 American Society of Clinical Oncology Gastrointestinal Cancer Symposium.

The combination of regorafenib plus an oral fluoropyrimidine, TAS-102, as third-line treatment in patients with metastatic colorectal cancer, achieved a clinically meaningful disease control rate in the phase I dose-escalation trial REMETY, according to data presented at the 2020 Gastrointestinal Cancers Symposium.

Better rates of overall survival were observed in patients with intermediate-stage hepatocellular carcinoma who had an elevated baseline alpha-fetoprotein level when ramucirumab was used as second-line therapy after sorafenib compared with second-line placebo. These improvements occurred irrespective of patients' Barcelona Clinic Liver Cancer stage and were based on results of a pooled analysis of the phase III REACH and REACH-2 trials

Joseph Chao, MD, discusses the importance of assessing the microsatellite instability (MSI) status in patients with advanced gastric/gastroesophageal junction cancer based on findings from a comparative analysis of KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062.